Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare

1,584 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OCUL Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Ocular

Therapeutix

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$25.38

▲(189.73% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $25.38 with a high forecast of $31.00 and a low forecast of $18.00. The average price target represents a 189.73% change from the last price of $8.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","11.75":"$11.75","18.5":"$18.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.75,18.5,25.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.98,12.52,14.06,15.600000000000001,17.14,18.68,20.22,21.76,23.3,24.84,26.380000000000003,27.92,29.46,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.98,12.087692307692308,13.195384615384615,14.303076923076922,15.41076923076923,16.518461538461537,17.626153846153848,18.73384615384615,19.841538461538462,20.949230769230766,22.056923076923077,23.16461538461538,24.27230769230769,{"y":25.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.98,11.52,12.06,12.6,13.14,13.68,14.219999999999999,14.76,15.3,15.84,16.38,16.92,17.46,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$31.00

Average Price Target$25.38

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Serge Belanger

Needham

$18

Buy

105.48%

Upside

Reiterated

03/02/26

Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix

William Maughan

Clear Street

$21→$28

Buy

219.63%

Upside

Reiterated

03/02/26

Ocular Therapeutix price target raised to $28 from $21 at Clear StreetOcular Therapeutix price target raised to $28 from $21 at Clear Street

Biren Amin

Piper Sandler

$31

Buy

253.88%

Upside

Reiterated

03/02/26

Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

03/02/26

OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD

Tazeen Ahmad

Bank of America Securities

$24→$27

Buy

208.22%

Upside

Reiterated

03/02/26

OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target

Tara Bancroft

TD Cowen

$14→$20

Buy

128.31%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Ocular Therapeutix (NASDAQ: OCUL) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)

Lisa Walter

RBC Capital

$30

Buy

242.47%

Upside

Reiterated

02/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jonathan Wolleben

Citizens JMP

―

Buy

―

Reiterated

02/17/26

Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens

Clara Dong

Jefferies

$28

Buy

219.63%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)

Yi Chen

H.C. Wainwright

$21

Buy

139.73%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Ocular Therapeutix (NASDAQ: OCUL)

Colleen M. Kusy

Robert W. Baird

$17→$24

Buy

173.97%

Upside

Reiterated

10/03/25

Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird

Daniil Gataulin

Chardan Capital

$21

Buy

139.73%

Upside

Initiated

09/15/25

Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan

Greg Harrison

Scotiabank

$22→$20

Buy

128.31%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

Dane Leone

Raymond James

$19

Buy

116.89%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Serge Belanger

Needham

$18

Buy

105.48%

Upside

Reiterated

03/02/26

Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix

William Maughan

Clear Street

$21→$28

Buy

219.63%

Upside

Reiterated

03/02/26

Ocular Therapeutix price target raised to $28 from $21 at Clear StreetOcular Therapeutix price target raised to $28 from $21 at Clear Street

Biren Amin

Piper Sandler

$31

Buy

253.88%

Upside

Reiterated

03/02/26

Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

03/02/26

OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD

Tazeen Ahmad

Bank of America Securities

$24→$27

Buy

208.22%

Upside

Reiterated

03/02/26

OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target

Tara Bancroft

TD Cowen

$14→$20

Buy

128.31%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Ocular Therapeutix (NASDAQ: OCUL) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)

Lisa Walter

RBC Capital

$30

Buy

242.47%

Upside

Reiterated

02/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jonathan Wolleben

Citizens JMP

―

Buy

―

Reiterated

02/17/26

Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens

Clara Dong

Jefferies

$28

Buy

219.63%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)

Yi Chen

H.C. Wainwright

$21

Buy

139.73%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Ocular Therapeutix (NASDAQ: OCUL)

Colleen M. Kusy

Robert W. Baird

$17→$24

Buy

173.97%

Upside

Reiterated

10/03/25

Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird

Daniil Gataulin

Chardan Capital

$21

Buy

139.73%

Upside

Initiated

09/15/25

Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan

Greg Harrison

Scotiabank

$22→$20

Buy

128.31%

Upside

Reiterated

08/06/25

Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)

Dane Leone

Raymond James

$19

Buy

116.89%

Upside

Reiterated

08/04/25

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

3 Months

xxx

Success Rate

19/29 ratings generated profit

Average Return

+17.31%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.52% of your transactions generating a profit, with an average return of +17.31% per trade.

1 Year

Biren AminPiper Sandler

Success Rate

11/15 ratings generated profit

Average Return

+15.51%

a rating ―

Copying Biren Amin's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +15.51% per trade.

2 Years

xxx

Success Rate

27/29 ratings generated profit

Average Return

+95.62%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.10% of your transactions generating a profit, with an average return of +95.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OCUL has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 25.38.

Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.32 with a range of -$0.38 to -$0.27. The previous quarter’s EPS was -$0.29. OCUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $12.56M with a range of $10.60M to $14.08M. The previous quarter’s sales results were $13.25M. OCUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year OCUL has Performed in-line its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 25.38.

What is OCUL’s upside potential, based on the analysts’ average price target?

Ocular Therapeutix has 189.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OCUL a Buy, Sell or Hold?

Ocular Therapeutix has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ocular Therapeutix’s price target?

The average price target for Ocular Therapeutix is 25.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $18.00. The average price target represents 189.73% Increase from the current price of $8.76.

What do analysts say about Ocular Therapeutix?

Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of OCUL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

OCUL Analyst Ratings

OCUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ocular Therapeutix

OCUL Analyst Recommendation Trends

OCUL Financial Forecast

OCUL Earnings Forecast

OCUL Sales Forecast

OCUL Stock Forecast FAQ

Detailed List of Analyst Forecasts